Skip to content

Japan’s Kyowa Kirin Eying $1 Billion Sale of Pharma Assets

  • Brewer’s subsidiary weighing sale of some international assets
  • Kyowa Kirin is working with an adviser on potential sale plan

Kyowa Kirin Co., the Japanese specialty pharmaceutical firm, is considering a sale of some of its international assets that could fetch about $1 billion, people familiar with the matter said. 

The Tokyo-listed arm of brewer Kirin Holdings Co. is working with a financial adviser to explore the potential divestment of certain assets from its Kyowa Kirin International Plc unit, the people said, asking not to be identified as the matter is private. The sale, which could include more established and mature products, has drawn interest from some strategic and financial investors, according to the people.